Conversation with The Cancer LetterFree Hudis: ASCO had the vision, but was low on resources CancerLinQ required December 11, 2023Vol.49 No.46By Paul Goldberg
News Analysis Dana-Farber’s bold split from the Brigham is a culmination of Boston oncology’s complicated history December 08, 2023Vol.49 No.45By Jacquelyn Cobb
As Bertagnolli steps in, NIH and FDA reenvision clinical trials and evidence generation December 08, 2023Vol.49 No.45By Matthew Bin Han Ong
Guest Editorial New leadership, vision for the Worldwide Innovative Network Consortium in precision oncology December 08, 2023Vol.49 No.45By Wafik S. El-Deiry
Guest Editorial Turning the page: Projections for cancer care in the coming year December 08, 2023Vol.49 No.45By Samyukta Mullangi
Letter To The Editor The field of population epigenetics is failing on rigor and reproducibility December 08, 2023Vol.49 No.45
NCI NCI needs a $250M raise in FY24 to maintain paylines, grant funding levels amid crippling continuing resolutions December 01, 2023Vol.49 No.44By Matthew Bin Han Ong
Vinay Prasad describes his Vanderbilt colleagues as “despicable,” raising new questions about physicians’ conduct on social media December 01, 2023Vol.49 No.44By Paul Goldberg
Conversation with The Cancer Letter Prasad could not have had patient data when he called Vanderbilt colleagues “despicable” December 01, 2023Vol.49 No.44By Paul Goldberg
